Acura Pharmaceuticals to Raise Approximately $7.6 Million From Institutional Healthcare Investors
01. Juli 2015 06:15 ET
|
Acura Pharmaceuticals, Inc.
PALATINE, IL--(Marketwired - July 01, 2015) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced it has entered into a Securities Purchase Agreement with certain institutional investors to...
Acura Pharmaceuticals USPTO Issues Notice of Allowance for Novel Limitx(TM) Abuse Deterrent Technology
29. Juni 2015 06:15 ET
|
Acura Pharmaceuticals, Inc.
PALATINE, IL--(Marketwired - June 29, 2015) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced receipt from the United...
Acura Pharmaceuticals Partners Its Methamphetamine Resistant Impede(R) Technology
16. Juni 2015 06:15 ET
|
Acura Pharmaceuticals, Inc.
PALATINE, IL--(Marketwired - June 16, 2015) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced that Acura has entered into a License and Development Agreement with Bayer Healthcare LLC to...
Acura Pharmaceuticals Announces First Quarter 2015 Financial Results
04. Mai 2015 16:15 ET
|
Acura Pharmaceuticals, Inc.
PALATINE, IL--(Marketwired - May 04, 2015) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse,...
Acura Pharmaceuticals to Host First Quarter 2015 Financial Results Conference Call on May 5, 2015
21. April 2015 16:10 ET
|
Acura Pharmaceuticals, Inc.
PALATINE, IL--(Marketwired - April 21, 2015) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company plans...
Acura Pharmaceuticals to Develop Abuse Deterrent Hydrocodone With Acetaminophen Tablets With Limitx(TM) Technology
09. April 2015 16:15 ET
|
Acura Pharmaceuticals, Inc.
PALATINE, IL--(Marketwired - April 09, 2015) - Acura Pharmaceuticals Inc. (NASDAQ: ACUR), announced today that it is initiating development of an immediate-release hydrocodone bitartrate with...
Acura Pharmaceuticals Reports Successful Topline Results From Nexafed(R) Extended-Release Clinical Study
23. März 2015 06:00 ET
|
Acura Pharmaceuticals, Inc.
PALATINE, IL--(Marketwired - March 23, 2015) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), today announced preliminary topline results from a pilot clinical study which demonstrated bioequivalence of...
Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2014 Financial Results
02. März 2015 16:15 ET
|
Acura Pharmaceuticals, Inc.
PALATINE, IL--(Marketwired - March 02, 2015) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse,...
Acura Pharmaceuticals to Host 2014
Financial Results Conference Call on March 3, 2015
23. Februar 2015 06:30 ET
|
Acura Pharmaceuticals, Inc.
PALATINE, IL--(Marketwired - February 23, 2015) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company...
Acura Pharmaceuticals Initiates Clinical Study of Meth-Resistant Nexafed(R) Extended-Release Formulations
16. Februar 2015 06:30 ET
|
Acura Pharmaceuticals, Inc.
PALATINE, IL--(Marketwired - February 16, 2015) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), today announced the initiation of treatment in a pilot clinical study of two experimental formulations of...